Bioethical challenges in the implementation of targeted anti-tumor therapies in low-resource settings: a perspective from Latin America

Abstract

Precision oncology has revolutionized cancer care in high-income countries, but its implementation in Latin American low-resource settings faces profound bioethical dilemmas. This study analyzes these challenges through the lens of social justice and equity. An integrative review was conducted following the Whittemore and Knafl framework. A systematic search was performed across PubMed, Scopus, SciELO, and LILACS (2015–2025). Thematic synthesis was applied to integrate empirical data with normative bioethical theories. Four major analytical themes were identified: 1) The innovation paradox and financial toxicity, where prohibitive pricing (exceeding 100,000 USD/year) violates distributive justice and leads to a biological penalty in survival; 2) Infrastructure deficits and epistemic injustice, highlighted by a 9.4% access rate to next-generation sequencing (NGS) and the risks of applying Eurocentric genomic data to admixed LA populations; 3) Research vulnerability, where clinical trials serve as survival strategies, compromising autonomy and informed consent; and 4) The judicialization dilemma, where individual court orders for high-cost drugs threaten systemic sustainability and equity. To prevent a genomic apartheid, Latin America must transition toward genomic sovereignty and frugal precision oncology. Bioethical frameworks in the region must prioritize protection ethics and social justice to ensure that scientific innovation does not exacerbate existing health inequities.

Keywords

targeted therapy / bioethics / Latin America / health equity / precision medicine / distributive justice

References

[1] Penchaszadeh VB. Ethical issues in genetics and public health in Latin America with a focus on Argentina. J Community Genet. 2015; 6: 223-30.

[2] Barrios CH, Reinert T, Werutsky G. Access to high-cost drugs for advanced breast cancer in Latin America, particularly trastuzumab. Ecancermedicalscience. 2019; 13: 898.

[3] Raez LE, Cardona AF, Santos ES, Catoe H, Rolfo C, Lopes G, et al. The burden of lung cancer in Latin America and challenges in the access to genomic profiling, immunotherapy and targeted treatments. Lung Cancer. 2018; 119: 7-13.

[4] de Castilla EMR, Mayrides M, González H, Vidangossy F, Corbeaux T, Ortiz N, et al. Implementing precision oncology in Latin America to improve patient outcomes: the status quo and a call to action for key stakeholders and decision-makers. Ecancermedicalscience. 2024; 18: 1653.

[5] Amayiri N, Al-Hussaini M, Maraqa B, Alyazjeen S, Alzoubi Q, Musharbash A, et al. Next-generation sequencing for pediatric CNS tumors: does it add value in a middle-income country setup? Front Oncol. 2024; 14: 1329024.

[6] Popejoy AB, Fullerton SM. Genomics is failing on diversity. Nature. 2016; 538: 161-4.

[7] Zavala VA, Bracci PM, Carethers JM, Carvajal-Carmona L, Coggins NB, Cruz-Correa MR, et al. Cancer health disparities in racial/ethnic minorities in the United States. Br J Cancer. 2020; 124: 315-32.

[8] Mastroleo I. Post-trial obligations in the Declaration of Helsinki 2013: classification, reconstruction and interpretation. Dev World Bioeth. 2016; 16: 80-90.

[9] Parker M, Kwiatkowski DP. The ethics of sustainable genomic research in Africa. Genome Biol. 2016; 17: 44.

[10] Andia TS, Lamprea E. Is the judicialization of health care bad for equity? A scoping review. Int J Equity Health. 2019; 18: 61.

[11] Riegler J. Comparative Ethics of Modern Payment Models. Voices Bioeth. 2023; 9.

[12] Whittemore R, Knafl K. The integrative review: updated methodology. J Adv Nurs. 2005; 52: 546-53.

[13] Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372: n71.

[14] Hong QN, Fàbregues S, Bartlett G, Boardman F, Cargo M, Dagenais P, et al. The Mixed Methods Appraisal Tool (MMAT) version 2018 for information professionals and researchers. Educ Inf. 2018; 34: 285-91.

[15] Thomas J, Harden A. Methods for the thematic synthesis of qualitative research in systematic reviews. BMC Med Res Methodol. 2008; 8: 45.

[16] Richard-Greenblatt M, Comar CE, Flevaud L, Berti M, Harris RM, Weiss SR, et al. Copan eNAT Transport System To Address Challenges in COVID-19 Diagnostics in Regions with Limited Testing Access. J Clin Microbiol. 2021; 59: e59.

[17] Desai AP, Scheckel CJ, Soderberg LC, Jensen CJ, Orme JJ, Tella SH, et al. Economic Cost and Sustainability of Oral Therapies in Precision Oncology. JCO Oncol Pract. 2022; 18: e1247-54.

[18] Elshiekh C, Rudà R, Cliff ERS, Gany F, Budhu JA. Financial challenges of being on long-term, high-cost medications. Neurooncol Pract. 2024; 12: i49-58.

[19] Sebastian R, Georgy JT, George A, Santhanam P, Philip R, Joel A, et al. Real World Outcomes with Tepotinib in a Series of Indian Patients with MET Exon 14 Skipping positive Non-Small Cell Lung Cancer. Ecancermedicalscience. 2025; 19: 1966.

[20] Kivuyo N, Akoko L, Mutajwaha JOG, Haule C, Mosha I, Misidai M, et al. Dismal pathological response to neoadjuvant chemotherapy in stage III breast cancer patients in Tanzania: A retrospective review. PLOS One. 2025; 20: e0321187.

[21] Zampoli M, Morrow BM, Paul G. Real-world disparities and ethical considerations with access to CFTR modulator drugs: Mind the gap! Front Pharmacol. 2023; 14: 1163391.

[22] Putra M, Annisa M, Ghozali S. P15.22.B unmasking socioeconomic inequities in Glioblastoma care: A systematic review of barriers to palliative and supportive services in Asia. Neuro Oncol. 2025; 27: iii152.

[23] Zafar SY, Peppercorn JM, Schrag D, Taylor DH, Goetzinger AM, Zhong X, et al. The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience. Oncologist. 2013; 18: 381-90.

[24] Smith GL, Lopez-Olivo MA, Advani PG, Ning MS, Geng Y, Giordano SH, et al. Financial Burdens of Cancer Treatment: A Systematic Review of Risk Factors and Outcomes. J Natl Compr Cancer Netw. 2019; 17: 1184-92.

[25] Martínez-Nava GA, Urbina-Jara LK, Lira-Albarrán S, Gómez HL, Ruiz-García E, Nieto-Coronel MT, et al. Somatic Mutations in Latin American Breast Cancer Patients: A Systematic Review and Meta-Analysis. Diagnostics. 2024; 14: 287.

[26] Zarić M, Čanović P, Živković Zarić R, Protrka S, Glišić M. The Three Musketeers in Cancer Therapy: Pharmacokinetics, Pharmacodynamics and Personalised Approach. J Pers Med. 2025; 15: 516.

[27] Corrarino JE. Health Literacy and Women’s Health: Challenges and Opportunities. J Midwifery Womens Health. 2013; 58: 257-64.

[28] Paasche-Orlow MK, Taylor HA, Brancati FL. Readability Standards for Informed-Consent Forms as Compared with Actual Readability. N Engl J Med. 2003; 348: 721-6.

[29] Amerson RM, Strang CW. Addressing the Challenges of Conducting Research in Developing Countries. J Nurs Scholarsh. 2015; 47: 584-91.

[30] Salha LA, Reis FC, Gonçalves RM, Lima JHDS, Salha NA, Pinto RP, et al. Judicialization of health: profile of demands for oncological medicines in a state in the central region of Brazil. Int J Equity Health. 2022; 21: 112.

[31] Yam C, Ma BBY, Yap TA. Global Implementation of Precision Oncology. JCO Precis Oncol. 2021; 5: 854-8.

[32] Salman P, de Melo AC, Rico-Restrepo M, Rodriguez J, Russi A, Schmerling RA, et al. Addressing the unmet needs of patients with BRAF-mutated melanoma in Latin America: Expert perspective. Front Oncol. 2023; 13: 1032300.

[33] Jimenez EB, Virtudazo JMP, Torres CE, Bernabe RD. Availability of post-trial access in clinical trials: a review of clinical trial protocols submitted to the research ethics board of the University of the Philippines Manila. Curr Med Res Opin. 2019; 35: 1849-55.

[34] Munung NS, Mayosi BM, de Vries J. Genomics research in Africa and its impact on global health: insights from African researchers. Glob Health Epidemiol Genom. 2018; 3: e12.

[35] Ambrosino E, Abou Tayoun AN, Abramowicz M, Zilfalil BA, Boughtwood T, Hamdi Y, et al. The WHO genomics program of work for equitable implementation of human genomics for global health. Nat Med. 2024; 30: 2711-3.

[36] Rotimi SO, Rotimi OA, Salhia B. Authorship Patterns in Cancer Genomics Publications Across Africa. JCO Glob Oncol. 2021; 7: 747-55.

[37] Neupane D, Khanal V. Implication of Public Health Genomics for Low and Middle Income Countries. Health Prospect. 2018; 10: 32-3.

[38] Vasconcellos VF, Colli LM, Awada A, de Castro Junior G. Precision oncology: as much expectations as limitations. Ecancermedicalscience. 2018; 12: ed86.

[39] Calderón-Aparicio A, Orue A. Precision oncology in Latin America: current situation, challenges and perspectives. Ecancermedicalscience. 2019; 13: 920.